Cancello, Giuseppe
(2009)
Prognosis and adjuvant treatment effects in very young women (below 35 years) with operable breast cancer.
[Tesi di dottorato]
(Unpublished)
Item Type: |
Tesi di dottorato
|
Lingua: |
English |
Title: |
Prognosis and adjuvant treatment effects in very young women (below 35 years) with operable breast cancer |
Creators: |
Creators | Email |
---|
Cancello, Giuseppe | UNSPECIFIED |
|
Date: |
27 November 2009 |
Number of Pages: |
39 |
Institution: |
Università degli Studi di Napoli Federico II |
Department: |
Biologia e patologia cellullare e molecolare "L. Califano" |
Scuola di dottorato: |
Medicina molecolare |
Dottorato: |
Oncologia ed endocrinologia molecolare |
Ciclo di dottorato: |
22 |
Coordinatore del Corso di dottorato: |
nome | email |
---|
Vecchio, Giancarlo | vecchio@unina.it |
|
Tutor: |
nome | email |
---|
De Placido, Sabino | sdponco@unina.it |
|
Date: |
27 November 2009 |
Number of Pages: |
39 |
Uncontrolled Keywords: |
breast cancer; immunohistochemistry; very young women |
Settori scientifico-disciplinari del MIUR: |
Area 06 - Scienze mediche > MED/06 - Oncologia medica |
[error in script]
[error in script]
Date Deposited: |
27 May 2010 14:48 |
Last Modified: |
30 Apr 2014 19:39 |
URI: |
http://www.fedoa.unina.it/id/eprint/3942 |
DOI: |
10.6092/UNINA/FEDOA/3942 |

Abstract
Background: There is limited knowledge about prognosis of selected breast cancer subtypes among very young women Patients and Methods: We explored patterns of recurrence by age according to four immunohistochemically-defined tumor subtypes: triple negative, HER2 positive (and) endocrine receptor absent, Luminal A and Luminal B (ER-positive and/or PR-positive and either HER2-positive and/or high Ki67) in 2970 premenopausal patients with pT1-3, pN0-3 and M0 breast cancer. Results: Patients below 35 years of age (315, 11%) presented a significantly increased risk of recurrence and death (HR=1.65, 95%CI 1.30-2.10 and HR=1.78, 95%CI 1.12-2.85, respectively) when compared with older patients (2655, 89%) with similar characteristics of disease. This was true considering patients with luminal B (HR 1.62, 95%CI, 1.21-2.18, for DFS; HR 2.09, 95%CI, 0.96-4.53, for OS) and with triple-negative (HR 2.04, 95%CI, 1.11-3.72, for DFS; HR 2.20, 95%CI, 1.10-4.41, for OS) breast cancer, observing the highest risk of recurrence in the younger patients with HER2 positive breast cancer (HR 2.37, 95% CI, 1.12-5.02), when compared with older patients. Conclusions: Very young patients with triple negative, luminal B, or HER2 positive breast cancer have a worse prognosis when compared with older patients with similar characteristics of disease.
Downloads per month over past year
Actions (login required)
 |
View Item |